scholarly journals Mania Induzida por Mirtazapina: Um Caso Clínico

2019 ◽  
Vol 32 (10) ◽  
pp. 671 ◽  
Author(s):  
Catarina Freitas ◽  
Rui Barranha ◽  
Tânia Abreu ◽  
Orlando Von Doellinger

Manic and hypomanic states associated with antidepressant treatments are relatively common; however, when specifically considering mirtazapine, those side effects are infrequent. The authors report a clinical case regarding a manic episode with dysphoric features in a patient with no personal or family previous psychiatric history. It began two weeks after starting treatment with mirtazapine up to 30 mg/day. This episode was treated discontinuing mirtazapine and initiating olanzapine (10 mg), with symptomatic remission. Mirtazapine has a specific pharmacodynamics, blocking not only post-synaptic serotonergic receptors but also α2-presynaptic adrenergic receptors. Taking this into consideration, it was hypothesized that this case could be attributed to a noradrenergic syndrome, characterized by dysphoria, irritability, insomnia and psychomotor agitation.

2021 ◽  
Vol 20 (3) ◽  
pp. 132-139
Author(s):  
А. L. Kozlova ◽  
М. Е. Leonteva ◽  
V. I. Burlakov ◽  
Z. А. Nesterenko ◽  
О. М. Laba ◽  
...  

The article is devoted to an extremely rare variant of type I interferonopathies associated with a homozygous gain of function (GOF) mutation in the STAT2 gene in a 5-year-old child. This genetic defect was first described in 2019, and so far only 3 cases are known in the world with a similar pathology. Here we present the fourth clinical case and our experience in managing a patient with STAT2 GOF. The article presents the key aspects of the pathogenesis, clinical picture based on the analysis of all known cases of the disease. The absence of established criteria and methods of treatment for this disease is due to the rarity and relative novelty of the described nosology. We present the experience of treatment using a JAK kinase inhibitor, followed by an assessment of the effectiveness of the therapy and side effects. The patient's parents agreed to use the information, including the child's photo, in scientific research and publications.


2017 ◽  
Vol 41 (S1) ◽  
pp. S430-S430
Author(s):  
A. Ballesteros ◽  
Á.S. Rosero ◽  
F. Inchausti ◽  
E. Manrique ◽  
H. Sáiz ◽  
...  

IntroductionMethylphenidate drugs is prescribed in attention deficit disorder and hyperactivity. Among its rare side effects, include alterations in the gynecological. We report a clinical case and review current evidence regarding the tolerability this drug in this area.MethodsWe performed a PubMed search of articles published in English of different types (case reports or case/controls studies). We collected the clinical practice guidelines conclusions regarding adverse drug reactions.Case presentationOur patient is a 14-year-old male diagnosed of ADHD treated with methylphenidate (0.8–1 mg\kg). He developed bilateral and asymmetric gynecomastia under this treatment plan so a referral was made to rule out other causes of this event. After performing several work up tests, it was concluded that this clinical presentation was caused by methylphenidate. Hence, we initiated crossed titration swapping this drug to atomoxetine. Four months later, he was mentally stable and he experimented a volumetric decrease as concerns his gynecomastia.As regards methylphenidate, in 2009 a couple of cases in which alterations in the sexual sphere presented with the oros presentation were reported. There are series of reported pharmacological side effects (gynecomastia) and also denoted an improvement of the same months after drug discontinuation.ConclusionsGynecological clinic secondary to the use of psychotropic drugs in ADHD is uncommon. In line with our case, the current evidence suggests a drug suspension as adverse effects are usually reversible (although it may take several months to complete recovery). Further studies are needed to understand the mechanisms underlying these tolerability issues.Disclosure of interestThe authors have not supplied their declaration of competing interest.


2018 ◽  
Vol 1 (1) ◽  
pp. 45
Author(s):  
Daniel Castro ◽  
Filipa Ferreira ◽  
Ana Sofia Mendes ◽  
Tiago Bento Ferreira

Background: The reasons for the high rates of comorbidity between Bipolar (BD) and Borderline Personality (BPD) disorders remain elusive, due to the vast array of shared clinical features, which makes the differential diagnosis difficult. This constitutes an obstacle to provide quality of care services, which results in detrimental effects on individual’s mental health. The analysis of the complex network of connections between symptoms of both disorders is a promising pathway to uncover the mechanisms underlying the comorbidity structure of both disorders. Goals: In this study, we explored the comorbidity network that represents the connections between 32 DSM-5 symptoms of BD and BPD in order to (1) compare its modular structure (i.e., the constitution of cohesive subgroups of symptoms within the comorbidity network) with the nosographic proposal of the DSM-5; (2) distinguish between the different roles those symptoms have in the comorbidity network and identify the symptoms that overlap and bridge both disorders, as well as the distinctive symptoms that better discriminate them; (3) identify the most central symptoms and those with the highest impact on the strength or on the structure of the connections on the comorbidity network; and (4) analyze the association between symptoms roles and their centrality and impact.Methods: An epidemiological sample from the National Comorbidity Survey: Baseline (NCS) was analyzed. Data regarding bipolar and borderline personality symptoms were collected through the Composite Network International Diagnostic Interview (CIDI). The network of complex interactions between symptoms was estimated using the Ising model with the L1-regularization penalty (EBIC) and the nosographic structure was detailed with Moduland algorithms. Results: Data regarding an overall sample of 7556 individuals was analyzed (48.6% male, Mage = 33.400 years, SDage = 10.447). Results revealed differences between the modular structure of the comorbidity network and the DSM-5 nosographic proposal, namely about unstable relationships and substance abuse, that were assigned to the module constituted by symptoms of manic episode (ME). Symptoms such as money spending and sexual indiscretions, that overlap ME and BPD in the DSM-5, were assigned to the ME module. Psychomotor agitation, which overlaps depressive episode (DE) and ME in the DSM-5, was assigned to the DE module. Additionally, emptiness and worthlessness were identified as bridge symptoms between DE and BPD; anger and substance abuse between ME and BPD; and unstable relationships and psychomotor agitation between DE and ME. Fatigue was the most distinctive symptom of the DE module, unstable relationships of the ME module, and anger of the BPD module. Strength centrality (r = .61, 95%CI [.33, .79], p < .001) and modular bridgeness (r = .64, 95%CI [.38, .81], p < .001) were positively correlated with the impact on the structure of the comorbidity network; and modular overlap was negatively correlated with the impact on the strength (r = -.43, 95%CI [-.10, -.68], p = .01) of its connections. Discussion: Results suggest a similar structure of the comorbidity network to the nosographic proposal of DSM-5. Distinctive and bridge symptoms were identified for each disorder which might help with the differential diagnosis. It can also help us to unveil possible development pathways of comorbidity that might promote an improvement in psychological treatments. Keywords: Bipolar disorder, Borderline personality disorder, Network analysis, Comorbidity.  


2015 ◽  
Vol 21 (3) ◽  
pp. 163-168 ◽  
Author(s):  
Olesea Scrinic ◽  
Seila Ibadula ◽  
E. Circo

ABSTRACT Introduction: Pacients with Down’s syndrome present an increase revalence of autoimune endocrine disorders. We communicate the case of 14 years and 6 months old pacient known with Down syndrome admitted in Endocrinology department with suspicion of hyperthyroidism, the diagnosis being confirmed by hormonal dosage. The particularity of the case consists in: symptomatology onset during puberty, clinical evolution with mild symptoms, without ocular involvement, morphological and functional remission obtained relatively soon after the initiation of antithyroid therapy, lack of posttherapy side effects, favorabile evolution under the “block and replace” therapy


2021 ◽  
Vol 2 (5) ◽  
pp. 21-24
Author(s):  
Liya A Lugovaya ◽  
◽  
Alexey A. Nekrasov ◽  
Leonid G. Strongin ◽  
Tatyana A. Nekrasova ◽  
...  

Statin-associated muscle symptoms are one of the statin-induced side effects. The incidence of the condition is increased by the presence of associated risk factors, one of which is hypothyroidism. The paper reports clinical case of statin-associated muscle symptoms in patient with compensated hypothyroidism carrying a SLCO1B1 mutation. Optimal assessment and treatment algorithms are discussed.


2020 ◽  
Vol 8 (2) ◽  
pp. 59
Author(s):  
Luísa Bandeira Lopes ◽  
Rodrigo Themudo ◽  
João Botelho ◽  
Vanessa Machado

Rhabdomyosarcoma is one of the most common soft-tissue sarcomas in children. The therapy for this condition has evolved significantly over recent decades, as has survival rates. Nevertheless, multiagent chemotherapy, radiation therapy, surgical resection or a combination of these modalities still have to be performed. This case report presents a 16-year-old boy with oral and dental effects after rhabdomyosarcoma treatment, diagnosed at the age of 4 years old. This report highlights the key role of dentists in the clinical management of rhabdomyosarcoma cases before, during and after treatment, and its potential side effects.


CNS Spectrums ◽  
2007 ◽  
Vol 12 (S22) ◽  
pp. 13-15

In spite of the tremendous advances made in developing antidepressant treatments and exploring augmentation with second-generation antipsychotics (SGAs), significant obstacles remain for psychiatrists: How should clinicians make use of cutting-edge augmentation studies? How should they use the antipsychotics in their treatment algorithm? How should they think about dosing and side effects?The first major problem is there have been no great algorithmic studies on adjunctive strategies. In fact, the most useful algorithmic study was the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, from which SGAs were entirely absent. The second problem is that STAR*D showed a clear pattern in which the efficacy of an augmentation agent depended on its placement in the algorithm. Those agents occurring later in the algorithm, such as monoamine oxidase inhibitors (MAOIs), adjunctive triiodothyronine (T3), and adjunctive lithium, appeared to be less effective than adjunctive buspirone, which occurred earlier in the algorithm. This was not the result of a direct comparison. Because of these two problems, it is therefore difficult to determine how to rank the efficacy of SGAs among the agents investigated by the STAR*D study. Among clinical treatment strategies, SGAs might appear toward the end of first-line strategies, perhaps after combinations and stimulants but before buspirone.


2016 ◽  
Vol 33 (S1) ◽  
pp. S331-S332
Author(s):  
L. Girardi ◽  
S. Gili ◽  
E. Gambaro ◽  
E. Di Tullio ◽  
E. Gattoni ◽  
...  

IntroductionAgitation is the most evident symptom in an acute manic episode. It can be defined as excessive motor or verbal activity that can degenerate into aggressive behaviour. Both aripiprazole and asenapine are indicated for the treatment of agitation in patients with manic episode.AimsTo retrospectively evaluate the acute effects of drug therapy on psychomotor agitation rated with the PANSS-EC, the change in manic symptoms through the YMRS, the QoL with the SF-36v2 and the cardiometabolic effects of the new oral APS.MethodsWe administered the following tests to 13 patients with DBI at T0 (baseline), T1 (after 1 week), T2 (after 4 weeks), T3 (after 12 weeks) and T4 (after 24 weeks): PANSS-EC, YMRS, SF-36v2, CGI-BD, CGI-S, HAM-D, BPRS. We also considered weight, height, BMI, ECG and complete blood count.ResultsPatients recruitment and statistical analyses are still in progress. Our preliminary results suggest that there is not a marked difference between the two drugs. We highlighted that there has been a noticeable decrease in results at PANSS as well as at YMRS from T0 to T4 and patients showed an improvement in QoL. Only one patient treated with asenapine showed an increase in the results of HAM-D.ConclusionsResults suggest the efficacy of the two new APS but further recruitment and data collection are needed to better understand their impact on agitation and QoL, including the metabolic profile, with the aim to help clinicians to make a more accurate choice of drug for each specific patient.Disclosure of interestThe authors have not supplied their declaration of competing interest.


Author(s):  
Dan V. Iosifescu ◽  
James W. Murrough ◽  
Dennis S. Charney

Since major depression is associated with significant morbidity and functional impairment, effective treatments are very important. This chapter reviews several categories of currently available antidepressant treatments (including the major classes of pharmacotherapies, somatic treatments, psychotherapies and natural remedies), attempting to review key findings regarding mechanisms of action, antidepressant efficacy and major side effects. We will also review significant data related to biomarkers of treatment outcome and to treatment of depression in special populations (e.g., psychotic, melancholic, atypical, postpartum, bipolar). We will conclude with a review of future antidepressant treatments currently in development.


Sign in / Sign up

Export Citation Format

Share Document